Archives20242023202220212020201920182017201620152014201320122011 March 30, 2020Subscription to raise £1.5 million to fund expansion of R&D pipeline Read More February 28, 2020Incanthera plc – Admission to trading on the NEX Exchange Growth Market Publication of Admission Document Read More February 17, 2020Oncology specialist Incanthera, in which ImmuPharma currently has a 14.0% shareholding, announces Rule 23 Notice in advance to quoting on NEX Exchange Growth Market Read More February 06, 2020ImmuPharma provides an update on the Avion Agreement in relation to Lupuzor’s™ new international Phase III trial Read More 1234
February 28, 2020Incanthera plc – Admission to trading on the NEX Exchange Growth Market Publication of Admission Document Read More
February 17, 2020Oncology specialist Incanthera, in which ImmuPharma currently has a 14.0% shareholding, announces Rule 23 Notice in advance to quoting on NEX Exchange Growth Market Read More
February 06, 2020ImmuPharma provides an update on the Avion Agreement in relation to Lupuzor’s™ new international Phase III trial Read More
